199 results on '"Barrón F"'
Search Results
2. CRACKING THE MEDICARE SECONDARY PAYER ENIGMA CODE
3. Decision Quality Using Ranked Attribute Weights
4. Linear Inequalities and the Analysis of Multi-Attribute Value Matrices
5. Conjoint Measurement and the Analysis of Noisy Data: A Comment
6. A Judgment-Based Definition of Materiality
7. Modeling the Materiality Judgements of Audit Partners
8. P45.11 Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer
9. P59.19 MET Alterations and Co-Drivers With Poor Prognosis in Patients With Metastatic Non-Small Cell Lung Cancer
10. P48.09 Body Mass Index Predicts Benefit From Adding Metformin to EGFR-TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT
11. P59.31 A High Number of Co-Current Genetic Alterations Is Associated With Poor Survival in EGFR Mutated Metastatic NSCLC Patients
12. OA17.03 Depression, Anxiety, and Distress Impact in Patients With Thoracic Malignancies During the COVID-19 Pandemic
13. Analysis of a Decision Making Investigation
14. Characterization of magnetic materials by low-field microwave absorption techniques
15. Nutrition Support in the Intensive Care Unit during the COVID19 pandemic
16. Applying learning from 1st to the 3rd wave of the COVID19 pandemic: nutritional provision in critical care
17. Nutrition in critical care: An audit of protein and energy intakes compared to international recommendations
18. PD2.03 Exploration of Factors Relating to Immune Response in Patients Treated with Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (NSCLC)
19. P2.25 Immunotherapy at Any Line of Treatment Improves Survival in Hispanic Patients with Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Compared with Chemotherapy (Quijote-CLICaP)
20. PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms
21. P2.24 Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy
22. P2.03 Normalization of Carcinoembryonic Antigen Levels Are Associated with a Survival Improvement in Advanced Non-Small Cell Lung Cancer Patients
23. P2.23 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
24. P1.12 Real World Characterization and Treatment Patterns of Patients with Thymic Carcinoma: Lessons from a Latin American Collaborative Study (CLICaP-LATimus)
25. PD1.05 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs)
26. P2.26 Budget Impact Analysis of Immunotherapy as Second-line Treatment of NSCLC at MX's National Institute of Cancer
27. P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients
28. PCN124 BUDGET IMPACT ANALYSIS OF IMMUNOTHERAPY AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AT MEXICO´S NATIONAL INSTITUTE OF CANCER
29. P1.10 Survival of Thymoma Is Extensive in Latin-American Patients: Results from over 10 Years of Experience (CLICaP-LATimus)
30. EP1.04-45 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced NSCLC (CLICAP-ABs)
31. EP1.04-46 Immunotherapy at Any Line Improves Survival in Hispanic Patients with Advanced Metastatic NSCLC Compared to Chemotherapy (Quijote-CLICaP)
32. EP1.04-47 Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab: Diagnostic and Therapeutic Challenge
33. P2.08-04 Stereotactic Ablative Radiation Therapy to Lung Metastases Associates with Better Outcomes in Oligometastatic Lung Cancer: Prospective Study
34. P1.14-61 EGFR Inhibitors Plus Bevacizumab Are Superior Compared to EGFR Inhibitor Monotherapy in Advanced EGFR+ NSCLC Patients with BIM Deletions
35. EP1.04-44 Exploration of Factors Relating to Paradoxical Immune Response in Patients Treated with Immune Checkpoint Inhibitors for NSCLC
36. MA07.08 The Role of a Cachexia Grading System in Patients with NSCLC Treated with Immunotherapy: Implications for Response and Survival
37. P2.01-40 Normalization of Carcinoembryonic Antigen Levels Is Associated with Survival Improvement in Patients with Advanced Non-Small Cell Lung Cancer
38. P2.09-28 Prognostic Impact of LKB1 Expression in Advanced Non-Small-Cell Lung Cancer
39. MA11.03 Pembrolizumab Plus Docetaxel Increases Progression-Free Survival Compared with Docetaxel Alone in Previously Treated Advanced Non-Small Cell Lung Cancer Patients
40. P1.04-80 Immunotherapy-Related Thrombosis: Considerations and Associated Factors in Non-Small Cell Lung Cancer (NSCLC) Patients
41. P2.14-43 Cost-Effectiveness of 1st-Line Treatment EGFR-TKIs for Advanced NSCLC Patients Harboring EGFR Mutation in Mexico
42. P1.04-81 Characterization of Hispanic Patients Who Experienced Hyperprogression During Treatment for Advanced NSCLC with Immunotherapy
43. An analysis of nutrition support in the intensive care unit during the covid19 pandemic
44. Applying learning from 1st to the 3rd wave of the covid19 pandemic: nutritional provision in critical care
45. MA02.08 The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial
46. PD.2.05 Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients
47. P03 Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells
48. Behavioral Decision Theory: A Topical Bibliography for Management Scientists
49. Payoff Matrices Pay off at Hallmark
50. Behavioral Risk Constraints in Investment Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.